EP0357240A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
EGF for preventing tissue damage after ischemia
Assignee: Ethicon Inc
•
Filing: 1989-08-03
•
Granted: —
•
Expires: 2009-08-03
Abstract
Abstract A method is provided for preventing tissue damage in a patient after the tissue has been deprived of blood supply resulting in ischemia. The method involves administering to the patient a polypeptide having epidermal growth factor activity or fibroblast growth factor activity prior to or after the ischemic event.
Inventors
- 👤 Warren D. Sheffield
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-01 13:30
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1825; A61K31/00; A61K38/1808; A61P; A61P43/00; A61P9/00; A61P9/10
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
62 words
The use of a polypeptide having epidermal growth factor activity in the manufacture of a medicament for use in a method of preventing tissue damage in a patient after the tissue has been deprived of blood supply for a tissue damaging amount of time, said method comprising administering the polypeptide to the patient so as to contact the blood deprived tissue therewith.
Claim 2
Dependent Claim
62 words
The use of a polypeptide having epidermal growth factor activity in the manufacture of a medicament for use in a method of preventing tissue damage in a patient after the tissue has been deprived of blood supply for a tissue damaging amount of time, said method comprising administering the polypeptide to the patient so as to contact the blood deprived tissue therewith.
Claim 3
Dependent Claim
25 words
The use of a polypeptide as claimed in claim 1 wherein the tissue is selected from neuronal tissue, myocardial tissue, lung tissue and renal tissue.
Claim 4
Dependent Claim
20 words
The use of a polypeptide as claimed in claim 1 or claim 2, wherein the polypeptide is epidermal growth factor.
Claim 5
Dependent Claim
21 words
The use of a polypeptide according to any preceding claim wherein the contacting is achieved by intravenous administration of the polypeptide.
Claim 6
Dependent Claim
32 words
The use of a polypeptide as claimed in any preceding claim, wherein said method comprises administering a fibrinolytic agent to the patient prior to or simultaneously with the administration of the polypeptide.
Claim 7
Dependent Claim
34 words
The use of a polypeptide as claimed in any preceding claim, wherein said method comprises administering a free radical scavenger material to the patient prior to or simultaneously with the administration of the polypeptide.
Claim 8
Dependent Claim
70 words
The use of a polypeptide having epidermal growth factor activity in the manufacture of a medicament for use in a method of preventing tissue damage in a patient resulting from the depravation of blood supply to the tissue for a tissue damaging amount of time, said method comprising administering the polypeptide to the patient, prior to the blood supply deprivation to the tissue, so as to contact the tissue therewith.
Claim 9
Dependent Claim
70 words
The use of a polypeptide having epidermal growth factor activity in the manufacture of a medicament for use in a method of preventing tissue damage in a patient resulting from the depravation of blood supply to the tissue for a tissue damaging amount of time, said method comprising administering the polypeptide to the patient, prior to the blood supply deprivation to the tissue, so as to contact the tissue therewith.
Claim 10
Dependent Claim
59 words
The use of a polypeptide having epidermal growth factor activity in the manufacture of a medicament for use in a method of preventing reperfusion injury to tissue in a patient after the tissue has suffered from ischemia, said method comprising administering the polypeptide to the patient in a reperfusion injury preventing amount so as to contact the tissue therewith.
Claim 11
Dependent Claim
59 words
The use of a polypeptide having epidermal growth factor activity in the manufacture of a medicament for use in a method of preventing reperfusion injury to tissue in a patient after the tissue has suffered from ischemia, said method comprising administering the polypeptide to the patient in a reperfusion injury preventing amount so as to contact the tissue therewith.
Claim 12
Dependent Claim
27 words
The use of a polypeptide having epidermal growth factor activity for use in a method of treating cerebrovascular disease in a patient resulting from an ischemic event.
Claim 13
Dependent Claim
27 words
The use of a polypeptide having epidermal growth factor activity for use in a method of treating cerebrovascular disease in a patient resulting from an ischemic event.
Claim 14
Dependent Claim
63 words
The use of a polypeptide having epidermal growth factor activity in the manufacture of a medicament for use in a method for preventing tissue damage in a patient after the tissue has been deprived of blood supply for a tissue damaging amount of time, said method comprising: a) administering to the patient a fibrinolytic agent, and b) administering to the patient said polypeptide.
Claim 15
Dependent Claim
63 words
The use of a polypeptide having epidermal growth factor activity in the manufacture of a medicament for use in a method for preventing tissue damage in a patient after the tissue has been deprived of blood supply for a tissue damaging amount of time, said method comprising: a) administering to the patient a fibrinolytic agent, and b) administering to the patient said polypeptide.
Claim 16
Dependent Claim
70 words
The use of a polypeptide having fibroblast growth factor activity for use in the manufacture of a medicament for use in a method of preventing neuronal and/or glial cell damage in the brain of a patient after such cells have been deprived of blood supply for a tissue damaging amount of time, said method comprising administering the polypeptide to the patient so as to contact the blood deprived tissue therewith.
Claim 17
Dependent Claim
70 words
The use of a polypeptide having fibroblast growth factor activity for use in the manufacture of a medicament for use in a method of preventing neuronal and/or glial cell damage in the brain of a patient after such cells have been deprived of blood supply for a tissue damaging amount of time, said method comprising administering the polypeptide to the patient so as to contact the blood deprived tissue therewith.
Claim 18
Dependent Claim
20 words
The use of a polypeptide as claimed in claim 11, wherein the polypeptide is basic or acidic fibroblast growth factor.
Claim 19
Dependent Claim
34 words
The use of a polypeptide as claimed in claim 11 or claim 12, wherein said method comprises administering a fibrinolytic agent to the patient prior to or simultaneously with the administration of the polypeptide.
Claim 20
Dependent Claim
36 words
The use of a polypeptide as claimed in any of claims 11 to 13, said method comprising administering a free radical scavenger material to the patient prior to or simultaneously with the administration of the polypeptide.
Claim 21
Dependent Claim
69 words
The use of a polypeptide having fibroblast growth factor activity in the manufacture of a medicament for use in a method of preventing neuronal and/or glial cell damage in the brain of a patient after such cells have been deprived of blood supply for a tissue damaging amount of time, said method comprising: a) administering a fibrinolytic agent to the patient; and b) administering said polypeptide to the patient.
Claim 22
Dependent Claim
69 words
The use of a polypeptide having fibroblast growth factor activity in the manufacture of a medicament for use in a method of preventing neuronal and/or glial cell damage in the brain of a patient after such cells have been deprived of blood supply for a tissue damaging amount of time, said method comprising: a) administering a fibrinolytic agent to the patient; and b) administering said polypeptide to the patient.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.